Zhejiang, China

Changlong Han


Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):

Title: Changlong Han: Innovator in Pharmaceutical Compositions

Introduction

Changlong Han is a notable inventor based in Zhejiang, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of kinase inhibitors. His work has led to advancements that may benefit the treatment of various diseases.

Latest Patents

Changlong Han holds 1 patent for his invention titled "Polymorphs of a kinase inhibitor, pharmaceutical compositions containing such a compound, preparation methods, and applications." This invention relates to new crystal forms of the compound (trans)-4-((2-cyclopropylethyl)amino)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl) cyclohexanol trihydrochloride, including its hydrate or solvate. The patent also covers methods for preparing the described compound and its crystal forms, as well as pharmaceutical compositions containing these compounds. Furthermore, it discusses the use of these compounds in the production of medicaments for treating various diseases, symptoms, or conditions.

Career Highlights

Changlong Han is associated with Meryx, Inc., where he continues to innovate in the pharmaceutical sector. His work has been instrumental in advancing the understanding and application of kinase inhibitors in medicine.

Collaborations

He has collaborated with notable colleagues, including Xiaodong Wang and Weihe Zhang, contributing to a dynamic research environment that fosters innovation.

Conclusion

Changlong Han's contributions to the field of pharmaceuticals, particularly through his patent on kinase inhibitors, highlight his role as an important inventor in the industry. His work has the potential to impact the treatment of various medical conditions significantly.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…